Go online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuvant, or perioperative immunotherapy in early-stage cancers, key trials and relevant endpoints, and evolving evidence supporting ICI use in different early-stage solid tumors, Implement best practices for multidisciplinary/interprofessional patient and tumor evaluation as well as coordination of care when managing patients with early-stage cancers, Integrate immunotherapies into individualized, multimodal treatment plans for appropriate patients with early-stage cancers in clinical practice or through clinical trial participation, Assess the risks and benefits associated with neoadjuvant/adjuvant/perioperative immunotherapy use to ensure safe, optimally selected, and appropriately timed delivery of systemic and local multimodal therapies to patients with early-stage solid tumors.
View all episodes
